- Opinion
- [Reporter's View] Super precision medicine
- by Eo, Yun-Ho Oct 30, 2024 05:53am
- Super Precision medicine. New drugs have been developed to selectively target with more significant efficacy than before. Lately, news articles related to anticancer agents have frequently covered keywords related to genetic mutations, including MET, RET, ALK, EGFR, and ROS1. Customized treatments are becoming available, where effective t
- Company
- "Early intervention" needed for treating multiple myeloma
- by Whang, byung-woo Oct 29, 2024 05:49am
- The survival rate of patients with multiple myeloma increased following new drug development. However, concerns have been raised that South Korea's survival rate is still far from that of advanced countries. Expert opinions indicate that the Korean medical treatment field changes with new drug approvals and reimbursement listings, yet patien
- Company
- Will the third time be the charm for Mylotarg?
- by Eo, Yun-Ho Oct 29, 2024 05:49am
- The industry’s attention is focused on whether the insurance reimbursement discussions for the acute myeloid leukemia drug ‘Mylotarg’ will make progress this time. According to the industry sources, Pfizer Korea’s acute myeloid leukemia (AML) drug ‘Mylotarg (gemtuzumab ozogamicin)’ is set to be submitted to the Health Insurance Revi
- Company
- ABL Bio receives ₩7B as milestone payment from Sanofi
- by Kim, Jin-Gu Oct 29, 2024 05:49am
- ABL Bio has received additional milestone payments from Sanofi for its degenerative brain disease treatment candidate ‘ABL301’. Including the upfront payment., ABL Bio will receive a total of KRW 170 billion, which includes the upfront payment. On 28 February, ABL Bio announced the completion of the manufacturing technology transfer o
- Policy
- Low reimb approval rate hinders Soliris’s use for aHUS
- by Lee, Tak-Sun Oct 29, 2024 05:49am
- The industry’s eyes are on whether the preliminary reimbursement review process for Soliris, a treatment for the rare disease aHUS (atypical hemolytic uremic syndrome), will be eased in Korea. Until now, patients wishing to use Soliris for aHUS with reimbursement had to pass a preliminary review process. However, the problem is its low
- Policy
- COVID-19 treatments 'Paxlovid·Veklury' reimb begins today
- by Lee, Jeong-Hwan Oct 28, 2024 05:54am
- Beginning today (October 25th), the National Health Insurance is applied to COVID-19 treatments, Paxlovid Tab (Pfizer Korea) and Veklury Inj (Gilead Sciences Korea). The patient copay will be maintained at the current cost of about KRW 50,000: KRW 47,090 for a single package of Paxlovid Tab (30 tablets) and KRW 49,920 (6 bottles) for Vekl
- Company
- 'Aquipta,' new oral migraine drug, can be prescribed
- by Eo, Yun-Ho Oct 28, 2024 05:53am
- AbbVie Korea's new drug 'Aquipta,' an oral drug used to treat migranes, is expanding the number of hospitals where it can be prescribed. According to industry sources, Aquipta (atogepant), an oral calcitonin gene-related peptide (GRRP) receptor antagonist for migraine treatment, has passed the drug committee (DC) of tertiary general hosp
- Company
- Will Roche’s lymphoma drug Columvi be discussed for reimb?
- by Eo, Yun-Ho Oct 28, 2024 05:53am
- Will Columvi, the first bispecific antibody treatment option for lymphoma, enter the first step to its reimbursement within the year? Roche Korea’s CD20-CD3 bispecific antibody for diffuse large B-cell lymphoma (DLBCL), Columvi (glofitamab), may likely be redeliberated by the Health Insurance Review and Assessment Service's Cancer Diseas
- Company
- "We have clinically proven Stelara for Koreans"
- by Moon, sung-ho Oct 28, 2024 05:53am
- Due to its wide variety of conditions, Crohn's disease requires customized long-term treatment depending on the disease type and inflammatory region. When treating patients with Crohn's disease, the location of the disease is challenging because the intestinal tract of the ileum (lower part of the small intestine) is narrow. Recently, the re
- Policy
- Switching between JAKis approved for atopic dermatitis
- by Lee, Tak-Sun Oct 28, 2024 05:53am
- Reimbursement for switching between severe atopic dermatitis drugs may be approved soon in Korea. However, further efforts by pharmaceutical companies would be needed to share the additional finances required. Therefore, it is analyzed that pharmaceutical companies will overcome the Health Insurance Review and Assessment Service’s review p
